Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

A Lightweight Risk Scoring System for Stratification of Newly Diagnosed Multiple Myeloma Patients

Georgia Riga, Vincent Luong, Katarina Uttervall, Gösta Gahrton, Hareth Nahi, Johan Lund, Evren Alici, Muhammad Kashif

Blood (2024) 144 (Supplement 1): 3318.

https://doi.org/10.1182/blood-2024-209504

Published: 2024

Journal Articles

A Novel Biosignature for Potential Stratification and Elucidation of Newly Diagnosed Multiple Myeloma Patients at-Risk

Muhammad Kashif, Yijie Zhou, Vincent Luong, Katarina Uttervall, Gösta Gahrton, Hareth Nahi, Evren Alici, Johan Lund

Blood (2023) 142 (Supplement 1): 1960.

https://doi.org/10.1182/blood-2023-179999

Published: 2023

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Evolution and Outcomes over More Than Two Decades within EBMT Centers

Blood (2014) 124 (21): 2554.

https://doi.org/10.1182/blood.V124.21.2554.2554

Published: 2014

Journal Articles

Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study

Blood (2013) 121 (25): 5055–5063.

https://doi.org/10.1182/blood-2012-11-469452

Published: 2013

Journal Articles

Risk Factors of Thromboembolic Events in Multiple Myeloma Treated with IMiDs-Based Therapy While on LMWH Prophylaxis,

Blood (2011) 118 (21): 3340.

https://doi.org/10.1182/blood.V118.21.3340.3340

Published: 2011

Journal Articles

Has Allogeneic Transplantation a Role in the Management of Plasma Cell Leukaemia? A Study on Behalf of the Myeloma Subcomittee of the Chronic Leukaemia Working Party of the EBMT

Curly Morris, MD, Simona Iacobelli, Gosta Gahrton, MD, Laurent Garderet, MD, Mary Drake, MBBCh, MD, Anja van Biezen, Mohamad Mohty, Didier Blaise, MD, Xavier Poiré, M.D, Marie José Kersten, Noel-Jean Milpied, MD, Stig Lenhoff, MD, PhD, Nigel H. Russell, MD, J.ürgen Finke, T. M. de Witte, MD, PhD

Blood (2011) 118 (21): 2008.

https://doi.org/10.1182/blood.V118.21.2008.2008

Published: 2011

Journal Articles

Approach to the treatment of multiple myeloma: a clash of philosophies

S. Vincent Rajkumar, Gösta Gahrton, P. Leif Bergsagel

Blood (2011) 118 (12): 3205–3211.

https://doi.org/10.1182/blood-2011-06-297853

Published: 2011

Journal Articles

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation

Blood (2011) 117 (23): 6063–6073.

https://doi.org/10.1182/blood-2011-02-297325

Published: 2011

Journal Articles

Bortezomib(Velcade®)-Thalidomide-Dexamethasone (VTD) Is Superior to Thalidomide-Dexamethasone (TD) In Patients with Multiple Myeloma (MM) Progressing or Relapsing After Autologous Transplantation

Blood (2010) 116 (21): 3043.

https://doi.org/10.1182/blood.V116.21.3043.3043

Published: 2010

Journal Articles

Tandem Autologous(ASCT)/ Allogeneic Reduced Intensity Conditioning Transplantation (RIC) with Identical Sibling Donor Versus ASCT in Previously Untreated Multiple Myeloma (MM): Long Term Follow up of a Prospective Controlled Trial by the EBMT.

Gosta Gahrton, MD, PhD, Bo Bjorkstrand, MD, PhD, Simona Iacobelli, Statistician, Ute Hegenbart, MD, Astrid Gruber, MD, PhD, Hildegard Greinix, MD, Liisa Volin, MD, Franco Narni, MD, Pellegrino Musto, MD, Meral Beksac, MD, Alberto Bosi, MD, Giuseppe Milone, MD, Paolo Corradini, MD, Hartmut Goldschmidt, MD, Theo de Witte, MD, Curly Morris, MD, Dietger Niederwieser, MD

Blood (2009) 114 (22): 52.

https://doi.org/10.1182/blood.V114.22.52.52

Published: 2009

Journal Articles

Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components

Evren Alici, Tolga Sutlu, Bo Björkstrand, Mari Gilljam, Birgitta Stellan, Hareth Nahi, Hernan Concha Quezada, Gösta Gahrton, Hans-Gustaf Ljunggren, M. Sirac Dilber

Blood (2008) 111 (6): 3155–3162.

https://doi.org/10.1182/blood-2007-09-110312

Published: 2008

Includes: Supplemental data

Journal Articles

Long Term Follow-Up Shows No Clinical Benefit for CD34 + Selection of Autologous Transplants Following Myeloablative Therapy in Patients with Newly Diagnosed Myeloma : An EBMT Phase III Randomized Study.

Jean-Henri Bourhis, MD, Yasmina Bouko, MD, Serge Koscielny, PhD, Hildegard Greinix, MD, Gunter Derigs, MD, Gilles Salles, MD, Walter Feremans, MD, Marleen Bakkus, PhD, Jane Apperley, MD, Diana Samson, MD, Bo Bjorkstrand, MD, Dietger Niederwieser, MD, Gosta Gahrton, MD, Jose-Luis Pico, MD, Hartmut Goldschmidt, MD

Blood (2004) 104 (11): 921.

https://doi.org/10.1182/blood.V104.11.921.921

Published: 2004

Journal Articles

Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma

Paolo Corradini, Michele Cavo, Henk Lokhorst, Giovanni Martinelli, Carolina Terragna, Ignazio Majolino, Pinuccia Valagussa, Mario Boccadoro, Diana Samson, Andrea Bacigalupo, Nigel Russell, Vittorio Montefusco, Claudia Voena, Gosta Gahrton, the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

Blood (2003) 102 (5): 1927–1929.

https://doi.org/10.1182/blood-2003-01-0189

Published: 2003

Journal Articles

Detailed Molecular Delineation of 13q14.3 Loss in B-Cell Chronic Lymphocytic Leukemia

Martin M. Corcoran, Omid Rasool, Yie Liu, Arati Iyengar, Dan Grander, Rachel E. Ibbotson, Mats Merup, Xiushan Wu, Vadim Brodyansky, Anne C. Gardiner, Gunnar Juliusson, Robert M. Chapman, Ganka Ivanova, Mary Tiller, Gosta Gahrton, Nick Yankovsky, Eugene Zabarovsky, David G. Oscier, Stefan Einhorn

Blood (1998) 91 (4): 1382–1390.

https://doi.org/10.1182/blood.V91.4.1382

Published: 1998

NARROW

A Lightweight Risk Scoring System for Stratification of Newly Diagnosed Multiple Myeloma Patients

A Novel Biosignature for Potential Stratification and Elucidation of Newly Diagnosed Multiple Myeloma Patients at-Risk

Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Evolution and Outcomes over More Than Two Decades within EBMT Centers

Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study

Risk Factors of Thromboembolic Events in Multiple Myeloma Treated with IMiDs-Based Therapy While on LMWH Prophylaxis,

Has Allogeneic Transplantation a Role in the Management of Plasma Cell Leukaemia? A Study on Behalf of the Myeloma Subcomittee of the Chronic Leukaemia Working Party of the EBMT

Approach to the treatment of multiple myeloma: a clash of philosophies

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation

Bortezomib(Velcade®)-Thalidomide-Dexamethasone (VTD) Is Superior to Thalidomide-Dexamethasone (TD) In Patients with Multiple Myeloma (MM) Progressing or Relapsing After Autologous Transplantation

Tandem Autologous(ASCT)/ Allogeneic Reduced Intensity Conditioning Transplantation (RIC) with Identical Sibling Donor Versus ASCT in Previously Untreated Multiple Myeloma (MM): Long Term Follow up of a Prospective Controlled Trial by the EBMT.

Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components

Long Term Follow-Up Shows No Clinical Benefit for CD34 + Selection of Autologous Transplants Following Myeloablative Therapy in Patients with Newly Diagnosed Myeloma : An EBMT Phase III Randomized Study.

Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma

Detailed Molecular Delineation of 13q14.3 Loss in B-Cell Chronic Lymphocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only